In conclusion, patients with advanced pancreatic cancer treated with gastrin receptor blockade using gastrazole appeared to live longer compared to placebo, albeit in a very small trial and will require confirmation with large-scale randomised studies. This evidence concerns the gene CCKBR and pancreatic neoplasm.